Navigation Links
Forge Therapeutics Scientific Co-Founder Bestowed Prestigious National Chemistry Award
Date:8/19/2015

SAN DIEGO, Aug. 19, 2015 /PRNewswire/ -- Forge Therapeutics, Inc., a biotechnology start-up developing novel small molecule inhibitors that target metalloproteins announced today Dr. Seth Cohen, Ph.D., co-founder of Forge Therapeutics and Professor in the Department of Chemistry and Biochemistry at the University of California, San Diego is the recipient of the Arthur C. Cope Scholar Award administered by the American Chemical Society. 

The Arthur C. Cope Scholar Award is a prize awarded for excellence and achievement in the field of organic chemistry.  Dr. Cohen was named one of the ten Arthur C. Cope Scholars at the American Chemical Society national meeting being held in Boston from August 16-20, 2015 for his pioneering work on metalloprotein chemistry. 

"It is with great pride at Forge Therapeutics that we congratulate Dr. Cohen on being named an Arthur C. Cope Scholar," said Zachary A. Zimmerman, Ph.D., CEO of Forge Therapeutics.  "This award is a high honor in the field of chemistry and further validates the Forge Therapeutics drug discovery platform."

To learn more about the Arthur C. Cope Scholar Award please visit: http://www.acs.org/content/acs/en/funding-and-awards/awards/national/recipients/2016-national-award-recipients.html

About Forge Therapeutics, Inc.

Forge Therapeutics, Inc. ("Forge") is a biotechnology start-up that leverages its novel chemistry platform to develop small molecule inhibitors to target metalloproteins.  Metalloproteins are proteins that require metal ions for their biological function and make up over 1/3 of the proteins in the human body.  Forge uses a proprietary approach comprised of molecular modeling for rational drug design along with fundamental knowledge and expertise in bioinorganic chemistry to target metalloproteins.  Forge is uniquely positioned to discover compounds that inhibit metalloproteins through an innovative process developed at the University of California at San Diego.  Forge possesses rights to key intellectual property for metalloprotein inhibitors. The name Forge Therapeutics comes from two definitions for forge: to manipulate (inhibit) a metal object (metalloprotein) and to move forward steadily with a purpose (the Forge team).  Forge Therapeutics, Inc., maintains its headquarters in San Diego, California.  To learn more please visit www.ForgeTherapeutics.com

Contact:
Info@ForgeTherapeutics.com

Logo - http://photos.prnewswire.com/prnh/20150807/256906LOGO


'/>"/>
SOURCE Forge Therapeutics, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. Forge Therapeutics Co-Founder to Present at the 250th American Chemical Society National Meeting
2. Forge Therapeutics Enters Into a Pilot Study with Janssen Research & Development, LLC, to Discover Novel Metalloprotein Inhibitors
3. Genedata and IntelliCyt Forge Alliance to Transform Cell-based Screening in Drug Discovery
4. Bynder and HubCast Forge Global Partnership for Transformative “Concept to Delivery” Solution
5. Never forget a face
6. Tor/Forge Launches THE CURE, a Riveting Thriller in the Tradition of Michael Crichton, by the New York Times Bestselling Author of WIRED.
7. Don't Forget the Payer in Your Digital Strategy: What Payers Need and Want from Pharma
8. Chrysalis BioTherapeutics TP508 Reverses Radiation-Induced GI Damage
9. PTC Therapeutics Announces Closing of $150 Million of Convertible Senior Notes
10. Echo Therapeutics, Inc. Provides Corporate Update and Announces Second Quarter 2015 Financial Results
11. BrainStorm Cell Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- On Thursday, March 23, 2017, the ... 0.07%; the Dow Jones Industrial Average edged 0.02% lower, ... at 2,345.96, marginally dropping 0.11%. US markets saw a ... sectors finished in red, and 1 sector ended flat ... coverage on the following Biotechnology equities: BioDelivery Sciences International ...
(Date:3/23/2017)... Research and Markets has announced the addition of ... offering. ... The Global Market for Bioproducts Should Reach $714.6 Billion ... of 8.9%, This research report quantifies the ... product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), biocomposite ...
(Date:3/23/2017)... ... 23, 2017 , ... Ellen Matloff, president and CEO of ... as a 2017 Women of Innovation® finalist. Matloff will be among several women ... The dinner recognizes women accomplished in science, technology, engineering and math (STEM), along ...
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
Breaking Biology Technology:
(Date:3/22/2017)... 21, 2017 Vigilant Solutions , a ... enforcement agencies, announced today the appointment of retired FBI ... public safety business development. Mr. Sheridan brings ... including a focus on the aviation transportation sector, to ... position, Mr. Sheridan served as the Aviation Liaison Agent ...
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
Breaking Biology News(10 mins):